Nicholas J Lynch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9001806/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Secondary Complement Deficiency Impairs Anti-Microbial Immunity to Klebsiella pneumoniae and Staphylococcus aureus During Severe Acute COVID-19. Frontiers in Immunology, 2022, 13, 841759.	2.2	5
2	Inhibition of the lectin pathway of complement ameliorates hypocomplementemia and restores serum bactericidal activity in patients with severe COVIDâ€19. Clinical and Translational Medicine, 2022, 12, .	1.7	6
3	Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins. Frontiers in Immunology, 2021, 12, 714511.	2.2	111
4	The Pneumococcal Surface Proteins PspA and PspC Sequester Host C4-Binding Protein To Inactivate Complement C4b on the Bacterial Surface. Infection and Immunity, 2019, 87, .	1.0	26
5	Lectin pathway effector enzyme mannanâ€binding lectinâ€associated serine proteaseâ€2 can activate native complement C3 in absence of C4 and/or C2. FASEB Journal, 2017, 31, 2210-2219.	0.2	43
6	Deficiency in Mannose-Binding Lectin-Associated Serine Protease-2 Does Not Increase Susceptibility to Trypanosoma cruzi Infection. American Journal of Tropical Medicine and Hygiene, 2015, 92, 320-324.	0.6	12
7	Mannanâ€binding lectinâ€associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4. FASEB Journal, 2014, 28, 3996-4003.	0.2	75
8	Low-dose recombinant properdin provides substantial protection against <i>Streptococcus pneumoniae</i> and <i>Neisseria meningitidis</i> infection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5301-5306.	3.3	48
9	Mannan-binding Lectin-associated Serine Proteases. , 2013, , 2857-2863.		Ο
10	The Lectin Pathway of Complement Activation Is a Critical Component of the Innate Immune Response to Pneumococcal Infection. PLoS Pathogens, 2012, 8, e1002793.	2.1	144
11	Absence of the lectin activation pathway of complement does not increase susceptibility to Pseudomonas aeruginosa infections. Immunobiology, 2012, 217, 272-280.	0.8	16
12	Use of recombinant calreticulin and cercarial transformation fluid (CTF) in the serodiagnosis of Schistosoma mansoni. Immunobiology, 2011, 216, 379-385.	0.8	23
13	Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7523-7528.	3.3	174
14	Mannan binding lectin associated serine protease-2 (MASP-2) is a critical player in the pathophysiology of renal ischaemia reperfusion (I/R) injury and mediates tissue injury in absence of complement C4. Molecular Immunology, 2009, 46, 2832.	1.0	5
15	Small Mannose-Binding Lectin-Associated Protein Plays a Regulatory Role in the Lectin Complement Pathway. Journal of Immunology, 2006, 177, 8626-8632.	0.4	81
16	Functional MASP2 single nucleotide polymorphism plays no role in psoriasis. British Journal of Dermatology, 2005, 152, 1313-1315.	1.4	12
17	Decoupling of Carbohydrate Binding and MASP-2 Autoactivation in Variant Mannose-Binding Lectins Associated with Immunodeficiency. Journal of Immunology, 2005, 175, 6846-6851.	0.4	11
18	Composition of the Lectin Pathway of Complement in <i>Gallus gallus</i> : Absence of Mannan-Binding Lectin-Associated Serine Protease-1 in Birds. Journal of Immunology, 2005, 174, 4998-5006.	0.4	51

NICHOLAS J LYNCH

#	Article	IF	CITATIONS
19	L-Ficolin Specifically Binds to Lipoteichoic Acid, a Cell Wall Constituent of Gram-Positive Bacteria, and Activates the Lectin Pathway of Complement. Journal of Immunology, 2004, 172, 1198-1202.	0.4	245
20	Organization of the MASP2 locus and its expression profile in mouse and rat. Mammalian Genome, 2004, 15, 887-900.	1.0	21
21	Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency. European Journal of Immunology, 2004, 34, 2589-2598.	1.6	69
22	Microglial activation and increased synthesis of complement component C1q precedes blood–brain barrier dysfunction in rats. Molecular Immunology, 2004, 40, 709-716.	1.0	86
23	Murine serine proteases MASP-1 and MASP-3, components of the lectin pathway activation complex of complement, are encoded by a single structural gene. Genes and Immunity, 2003, 4, 374-384.	2.2	14
24	Differential Expression of the Murine Mannose-Binding Lectins A and C in Lymphoid and Nonlymphoid Organs and Tissues. Journal of Immunology, 2003, 170, 1462-1465.	0.4	90
25	In Vivo Biosynthesis of Endogenous and of Human C1 Inhibitor in Transgenic Mice: Tissue Distribution and Colocalization of Their Expression. Journal of Immunology, 2002, 169, 5948-5954.	0.4	14
26	In vivo pharmacokinetics of calreticulin S-domain, an inhibitor of the classical complement pathway. International Immunopharmacology, 2002, 2, 415-422.	1.7	8
27	Mutation detection and physical mapping of the CD11 gene cluster in association with inflammatory bowel disease. Immunogenetics, 2002, 53, 835-842.	1.2	10
28	The human gene for mannan-binding lectin-associated serine protease-2 (MASP-2), the effector component of the lectin route of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2–3. Genes and Immunity, 2001, 2, 119-127.	2.2	42
29	Microfibril-associated Protein 4 Is Present in Lung Washings and Binds to the Collagen Region of Lung Surfactant Protein D. Journal of Biological Chemistry, 1999, 274, 32234-32240.	1.6	56
30	Linkage of Inflammatory Bowel Disease to Human Chromosome 6p. American Journal of Human Genetics, 1999, 65, 1647-1655.	2.6	215
31	Interaction of C1q and the Collectins with the Potential Receptors Calreticulin (cClqR/Collectin) Tj ETQq1 1 0.784	4314 rgBT 0.8	/Overlock 1 87
32	Neuronal expression of fractalkine in the presence and absence of inflammation. FEBS Letters, 1998, 439, 203-207.	1.3	96
33	Characterisation of the rat and mouse homologues of gC1qBP, a 33 kDa glycoprotein that binds to the globular `heads' of C1q. FEBS Letters, 1997, 418, 111-114.	1.3	27
34	The C1q and collectin binding site within C1 q receptor (cell surface calreticulin). Immunopharmacology, 1997, 38, 73-80.	2.0	87
35	Localisation of the C1q binding site within C 1 q receptor/calreticulin. FEBS Letters, 1996, 397, 245-249.	1.3	53